Annual Revenue
$829.25 M
+$169.14 M+25.62%
31 December 2023
Summary:
Halozyme Therapeutics annual revenue is currently $829.25 million, with the most recent change of +$169.14 million (+25.62%) on 31 December 2023. During the last 3 years, it has risen by +$385.94 million (+87.06%). HALO annual revenue is now at all-time high.HALO Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$290.08 M
+$58.73 M+25.39%
30 September 2024
Summary:
Halozyme Therapeutics quarterly revenue is currently $290.08 million, with the most recent change of +$58.73 million (+25.39%) on 30 September 2024. Over the past year, it has increased by +$60.05 million (+26.10%). HALO quarterly revenue is now at all-time high.HALO Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$947.36 M
+$74.05 M+8.48%
30 September 2024
Summary:
Halozyme Therapeutics TTM revenue is currently $947.36 million, with the most recent change of +$74.05 million (+8.48%) on 30 September 2024. Over the past year, it has increased by +$118.10 million (+14.24%). HALO TTM revenue is now at all-time high.HALO TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +26.1% | +14.2% |
| 3 y3 years | +87.1% | +184.4% | +113.7% |
| 5 y5 years | +323.1% | +440.6% | +383.4% |
HALO Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +209.9% | at high | +184.4% | at high | +113.7% |
| 5 y | 5 years | at high | +446.1% | at high | +1044.1% | at high | +476.3% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high |
Halozyme Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $290.08 M(+25.4%) | $947.36 M(+8.5%) |
| June 2024 | - | $231.35 M(+18.1%) | $873.30 M(+1.2%) |
| Mar 2024 | - | $195.88 M(-14.8%) | $862.99 M(+4.1%) |
| Dec 2023 | $829.25 M(+25.6%) | $230.04 M(+6.5%) | $829.25 M(+6.2%) |
| Sept 2023 | - | $216.03 M(-2.3%) | $780.71 M(+0.9%) |
| June 2023 | - | $221.04 M(+36.3%) | $773.65 M(+9.7%) |
| Mar 2023 | - | $162.14 M(-10.7%) | $704.98 M(+6.8%) |
| Dec 2022 | $660.12 M(+48.9%) | $181.50 M(-13.1%) | $660.12 M(+13.7%) |
| Sept 2022 | - | $208.98 M(+37.2%) | $580.62 M(+19.1%) |
| June 2022 | - | $152.37 M(+29.9%) | $487.48 M(+3.4%) |
| Mar 2022 | - | $117.28 M(+15.0%) | $471.57 M(+6.4%) |
| Dec 2021 | $443.31 M(+65.7%) | $102.00 M(-11.9%) | $443.31 M(-4.3%) |
| Sept 2021 | - | $115.83 M(-15.1%) | $463.01 M(+12.2%) |
| June 2021 | - | $136.46 M(+53.3%) | $412.50 M(+24.5%) |
| Mar 2021 | - | $89.02 M(-26.9%) | $331.26 M(+23.8%) |
| Dec 2020 | $267.59 M(+36.5%) | $121.70 M(+86.3%) | $267.59 M(+34.1%) |
| Sept 2020 | - | $65.32 M(+18.3%) | $199.56 M(+10.6%) |
| June 2020 | - | $55.22 M(+117.8%) | $180.47 M(+9.8%) |
| Mar 2020 | - | $25.35 M(-52.8%) | $164.40 M(-16.1%) |
| Dec 2019 | $195.99 M(+29.1%) | $53.66 M(+16.1%) | $195.99 M(-3.2%) |
| Sept 2019 | - | $46.23 M(+18.1%) | $202.56 M(+11.4%) |
| June 2019 | - | $39.15 M(-31.3%) | $181.88 M(+2.2%) |
| Mar 2019 | - | $56.95 M(-5.5%) | $177.94 M(+17.2%) |
| Dec 2018 | $151.86 M(-52.0%) | $60.23 M(+135.7%) | $151.86 M(-46.0%) |
| Sept 2018 | - | $25.56 M(-27.4%) | $281.19 M(-12.0%) |
| June 2018 | - | $35.20 M(+14.0%) | $319.37 M(+0.5%) |
| Mar 2018 | - | $30.87 M(-83.7%) | $317.92 M(+0.4%) |
| Dec 2017 | $316.61 M(+115.8%) | $189.56 M(+197.4%) | $316.61 M(+90.7%) |
| Sept 2017 | - | $63.73 M(+88.8%) | $166.05 M(+23.8%) |
| June 2017 | - | $33.75 M(+14.1%) | $134.17 M(+0.3%) |
| Mar 2017 | - | $29.57 M(-24.2%) | $133.76 M(-8.8%) |
| Dec 2016 | $146.69 M(+8.6%) | $39.00 M(+22.4%) | $146.69 M(-8.3%) |
| Sept 2016 | - | $31.85 M(-4.4%) | $159.91 M(+7.4%) |
| June 2016 | - | $33.34 M(-21.6%) | $148.84 M(-6.3%) |
| Mar 2016 | - | $42.50 M(-18.6%) | $158.89 M(+17.6%) |
| Dec 2015 | $135.06 M(+79.3%) | $52.23 M(+151.3%) | $135.06 M(+19.3%) |
| Sept 2015 | - | $20.78 M(-52.1%) | $113.21 M(+5.8%) |
| June 2015 | - | $43.38 M(+132.4%) | $107.03 M(+30.5%) |
| Mar 2015 | - | $18.67 M(-38.6%) | $82.03 M(+8.9%) |
| Dec 2014 | $75.33 M | $30.38 M(+108.0%) | $75.33 M(+31.1%) |
| Sept 2014 | - | $14.61 M(-20.6%) | $57.45 M(-2.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | $18.39 M(+53.6%) | $58.86 M(+7.2%) |
| Mar 2014 | - | $11.97 M(-4.3%) | $54.93 M(+0.2%) |
| Dec 2013 | $54.80 M(+29.5%) | $12.50 M(-22.0%) | $54.80 M(-14.5%) |
| Sept 2013 | - | $16.01 M(+10.8%) | $64.09 M(+20.0%) |
| June 2013 | - | $14.45 M(+22.1%) | $53.42 M(+14.3%) |
| Mar 2013 | - | $11.83 M(-45.7%) | $46.72 M(+10.4%) |
| Dec 2012 | $42.33 M(-24.5%) | $21.79 M(+308.6%) | $42.33 M(+84.5%) |
| Sept 2012 | - | $5.33 M(-31.2%) | $22.94 M(-43.4%) |
| June 2012 | - | $7.76 M(+4.3%) | $40.55 M(-27.6%) |
| Mar 2012 | - | $7.44 M(+208.6%) | $55.98 M(-0.2%) |
| Dec 2011 | $56.09 M(+311.7%) | $2.41 M(-89.5%) | $56.09 M(-2.0%) |
| Sept 2011 | - | $22.94 M(-1.1%) | $57.25 M(+51.8%) |
| June 2011 | - | $23.19 M(+207.4%) | $37.70 M(+112.7%) |
| Mar 2011 | - | $7.54 M(+111.2%) | $17.73 M(+30.1%) |
| Dec 2010 | $13.62 M(-0.3%) | $3.57 M(+5.2%) | $13.62 M(-17.4%) |
| Sept 2010 | - | $3.40 M(+5.7%) | $16.50 M(+2.3%) |
| June 2010 | - | $3.21 M(-6.6%) | $16.13 M(+12.5%) |
| Mar 2010 | - | $3.44 M(-46.6%) | $14.34 M(+4.9%) |
| Dec 2009 | $13.67 M(+56.0%) | $6.44 M(+112.7%) | $13.67 M(+32.9%) |
| Sept 2009 | - | $3.03 M(+112.4%) | $10.29 M(+5.8%) |
| June 2009 | - | $1.43 M(-48.6%) | $9.72 M(-0.1%) |
| Mar 2009 | - | $2.77 M(-9.5%) | $9.73 M(+11.0%) |
| Dec 2008 | $8.76 M(+130.7%) | $3.06 M(+24.4%) | $8.76 M(+24.5%) |
| Sept 2008 | - | $2.46 M(+71.7%) | $7.04 M(+27.5%) |
| June 2008 | - | $1.43 M(-20.6%) | $5.52 M(+15.1%) |
| Mar 2008 | - | $1.81 M(+35.0%) | $4.79 M(+26.2%) |
| Dec 2007 | $3.80 M(+287.0%) | $1.34 M(+41.9%) | $3.80 M(+31.6%) |
| Sept 2007 | - | $942.90 K(+33.1%) | $2.89 M(+25.2%) |
| June 2007 | - | $708.50 K(-12.6%) | $2.31 M(+34.3%) |
| Mar 2007 | - | $810.20 K(+90.1%) | $1.72 M(+75.1%) |
| Dec 2006 | $981.70 K(+671.8%) | $426.30 K(+17.6%) | $981.80 K(+60.6%) |
| Sept 2006 | - | $362.50 K(+202.8%) | $611.40 K(+122.7%) |
| June 2006 | - | $119.70 K(+63.3%) | $274.50 K(+36.9%) |
| Mar 2006 | - | $73.30 K(+31.1%) | $200.50 K(+57.6%) |
| Dec 2005 | $127.20 K(+415.0%) | $55.90 K(+118.4%) | $127.20 K(+78.4%) |
| Sept 2005 | - | $25.60 K(-44.0%) | $71.30 K(+56.0%) |
| June 2005 | - | $45.70 K(-185.6%) | $45.70 K(>+9900.0%) |
| Dec 2002 | - | -$53.40 K(-419.8%) | $0.00(-100.0%) |
| Sept 2002 | - | $16.70 K(+114.1%) | $53.40 K(+45.5%) |
| June 2002 | - | $7800.00(-73.0%) | $36.70 K(+27.0%) |
| Mar 2002 | - | $28.90 K | $28.90 K |
| Dec 2001 | $24.70 K | - | - |
FAQ
- What is Halozyme Therapeutics annual revenue?
- What is the all time high annual revenue for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly revenue year-on-year change?
- What is Halozyme Therapeutics TTM revenue?
- What is the all time high TTM revenue for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM revenue year-on-year change?
What is Halozyme Therapeutics annual revenue?
The current annual revenue of HALO is $829.25 M
What is the all time high annual revenue for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual revenue is $829.25 M
What is Halozyme Therapeutics quarterly revenue?
The current quarterly revenue of HALO is $290.08 M
What is the all time high quarterly revenue for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly revenue is $290.08 M
What is Halozyme Therapeutics quarterly revenue year-on-year change?
Over the past year, HALO quarterly revenue has changed by +$60.05 M (+26.10%)
What is Halozyme Therapeutics TTM revenue?
The current TTM revenue of HALO is $947.36 M
What is the all time high TTM revenue for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM revenue is $947.36 M
What is Halozyme Therapeutics TTM revenue year-on-year change?
Over the past year, HALO TTM revenue has changed by +$118.10 M (+14.24%)